Lumos Pharma, Inc. financial data

Symbol
LUMO on Nasdaq
Industry
Pharmaceutical Preparations
Location
4200 Marathon Blvd., Suite 200, Austin, Texas
State of incorporation
Delaware
Fiscal year end
December 31
Former names
NEWLINK GENETICS CORP (to 3/20/2020)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 709 % -47.7%
Debt-to-equity 39.5 % +117%
Return On Assets -85.9 % -110%
Operating Margin -2.59 K % -68.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.11 M shares -1.37%
Common Stock, Shares, Outstanding 8.11 M shares -0.93%
Entity Public Float 21.5 M USD -53.7%
Weighted Average Number of Shares Outstanding, Basic 8.1 M shares -1.64%
Weighted Average Number of Shares Outstanding, Diluted 8.1 M shares -1.64%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.53 M USD -27.5%
Revenue from Contract with Customer, Excluding Assessed Tax 1.53 M USD -27.5%
Research and Development Expense 25 M USD +38.7%
General and Administrative Expense 16 M USD -2.74%
Operating Income (Loss) -39.4 M USD -21.9%
Nonoperating Income (Expense) 2.28 M USD +39%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -34.1 M USD -9.62%
Income Tax Expense (Benefit) -29 K USD -123%
Net Income (Loss) Attributable to Parent -37.1 M USD -21%
Earnings Per Share, Basic -4.58 USD/shares -24.5%
Earnings Per Share, Diluted -4.58 USD/shares -24.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 23.2 M USD -47.4%
Cash, Cash Equivalents, and Short-term Investments 36.1 M USD -46.4%
Assets, Current 27.5 M USD -56.5%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 534 K USD +27.1%
Assets 28.1 M USD -55.9%
Accounts Payable, Current 569 K USD -32%
Employee-related Liabilities, Current 1.75 M USD +8.35%
Accrued Liabilities, Current 3.55 M USD -10%
Liabilities, Current 4.41 M USD -12%
Operating Lease, Liability, Noncurrent 225 K USD +19%
Liabilities 10.6 M USD -5.06%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -172 M USD -27.5%
Stockholders' Equity Attributable to Parent 17.4 M USD -66.8%
Liabilities and Equity 28.1 M USD -55.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.9 M USD -40.2%
Net Cash Provided by (Used in) Financing Activities -5 K USD +98.4%
Net Cash Provided by (Used in) Investing Activities 1 M USD
Common Stock, Shares Authorized 75 M shares 0%
Common Stock, Shares, Issued 8.13 M shares -0.83%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.9 M USD +0.59%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 23.2 M USD -47.4%
Deferred Tax Assets, Valuation Allowance 133 M USD +9.52%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 133 M USD +9.52%
Operating Lease, Liability 585 K USD +151%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -37.1 M USD -21%
Lessee, Operating Lease, Liability, to be Paid 652 K USD +176%
Operating Lease, Liability, Current 293 K USD +26.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 303 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 332 K USD +40.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +233%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 67 K USD +2133%
Lessee, Operating Lease, Liability, to be Paid, Year Three 17 K USD
Deferred Tax Assets, Operating Loss Carryforwards 39 M USD +10.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5 M shares 0%
Additional Paid in Capital 190 M USD +1.11%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) -29 K USD -123%
Depreciation, Depletion and Amortization 2 K USD -77.8%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 2.32 M USD -1.07%
Interest Expense 0 USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%